CLOVIS ONCOLOGY INC

NASDAQ: CLVS
$4.82
-$0.07 (-1.4%)
Closing price August 14, 2020
A new Merrill Lynch research report makes the case that four top biotech companies the firm covers have some powerful catalysts that could drive performance this year.
Merrill Lynch has taken a look at the biotech industry and made a few picks that could play out in 2018.
The include Albermarle, Best Buy, Chipotle Mexican Grill, Exact Sciences, Fitbit, Itron, NuVasive, Palo Alto Networks and Stryker.
These are four top companies for more aggressive investors looking for health care exposure to consider.
The top analyst upgrades, downgrades and other research calls from Monday include Biogen, Equifax, Foot Locker, General Electric, NVIDIA, Rio Tinto and Roku.
The top analyst upgrades, downgrades and other research calls from Friday include AK Steel, Altice USA, Biogen, Caterpillar, Gilead Sciences and Oracle.
Clovis Oncology saw its shares make a handy gain in Wednesday’s session after the company priced its secondary offering.
The top analyst upgrades, downgrades and other research calls from Tuesday include American Express, ADP, Goodyear Tire, McDonald's, National Oilwell Varco, NVIDIA and Vivint Solar.
Clovis Oncology saw its shares make a massive gain early on Monday after the company announced top-line data from its confirmatory Phase 3 trial of its treatment of ovarian cancer.
The top analyst upgrades, downgrades and other research calls on Wednesday include Advanced Micro Devices, ConocoPhillips, Etsy, Marathon Oil, Square, Walt Disney and Windstream.
The analysts at Merrill Lynch have raised their price targets on some stocks that have shown solid earnings growth and look poised to continue to deliver solid results for the rest of 2017.
The top analyst upgrades, downgrades and initiations include Alcoa, Altria, Ford, GoPro, NVIDIA, International Paper and Transocean.
The top analyst upgrades, downgrades and initiations seen on Thursday include Hasbro, Johnson & Johnson, Mattel, MetLife, United Rentals, United Technologies and Williams Companies.
To kick off the New Year, Clovis Oncology a few other biotech companies made massive runs on this first day of trading in 2017.
Companies receiving analyst upgrades, downgrades, initiations or other key notes on Tuesday morning include Alcoa, Arch Coal, Baidu, Ciena, JD.com and Vale.